The principles of pain control in cancer have not changed over the past four years, but our understanding of opioids has increased in many areas. This update reviews recent developments and new knowledge in morphine pharmacokinetics, new and established opioids, opioid actions and routes of opioid administration, including spinal routes.
Hanks GW, Hoskin PJOpioid analgesics in the management of pain in patients with cancer. A review . Palliative Medicine1987; 1: 1-25.
2.
White ID, Hoskin PJ, Hanks GW, Bliss JMAnalgesics in cancer pain. An investigation of physicians preference. Pain1990; Suppl 5: S360.
3.
World Health Organisation.Cancer Pain Relief . Geneva: World Health Organisation , 1986.
4.
Walker VA, Hoskin PJ, Hanks GW, White IDEvaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. Journal of Pain and Symptom Management1988; 3: 145-49.
5.
Takeda F.Results of field-testing in Japan of the WHO Draft Interim Guidelines on relief of cancer pain. The Pain Clinic1986; 1: 83-89.
6.
Ventafridda V., Tamburini M., Caraceni A., DeConno F., Nabli F.A validation study of the WHO method for cancer pain relief. Cancer1987; 59: 850-56.
7.
Stjernsward J.The WHO Cancer Pain Relief Programme. Cancer Surveys1988; 7: 195-208.
8.
Marks RM, Sacher EJUndertreatment of medical inpatients with narcotic analgesics. Ann Intern Med1973; 78: 173-81.
9.
Kanner RM, Foley KMPatterns of narcotic use in a cancer pain clinic. Ann NY Acad Sci1981; 362: 162-72.
10.
Walsh TD, Baxter R., Bowerman K., Leber B.High-dose morphine and respiratory function in chronic cancer pain. Pain1981; 51: 39.
11.
Elliott TE, Elliott BAPhysician attitudes and knowledge about the use of morphine for cancer pain . Pain1990; Suppl 5: S356.
12.
Gostick W. et al. A comparison of the efficacy and adverse effects of controlled release dihydrocodeine and immediate release dihydrocodeine in the treatment of pain in osteoarthritis and chronic back pain. In: Twycross R ed, The Edinburgh Symposium on Pain Control and Medical Education. Royal Society of Medicine Symposium Series, No. 149. 1989: 137-43.
13.
Hanks GWThe clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain. Drug Alcohol Depend1987; 20: 339-46.
14.
Ellis R., Haines D., Shah R., Cotton BP, Smith G.Pain relief after abdominal surgery - a comparison of IM morphine, sublingual buprenorphine and self-administered IV pethidine. Br J Anaesth1982; 54: 421-28.
15.
Hanks GWPain in the jungle. Br Med J1988; 296: 431.
16.
Robbie DSA trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol1979; 7: 315-17.
17.
Adriaensen H., Mattelaere B., Vanmeenan H.A longterm open assessment of sublingual buprenorphine in patients suffering from chronic pain. Pain1981; S38: 538.
18.
Heel RC, Brogden RN, Speight TM, Avery GSBuprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs1979; 17: 81-110.
19.
Zenz M., Piepenbrock S., Tryba M., Glocke M., Everlein M., Klauke W.Kontrollierle Studie mit Buprenorphine. Deutsche Medizinische Wectienschrift1985; 110: 448-53.
20.
Gray RF, Ferry A., Jauhar P.Emergence of buprenorphine dependence. Br J Addict1989; 84: 1373-74.
21.
Cowan A., Doxey JC, Harry Ejr.The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol1977; 60: 547-54.
22.
Atkinson RE , Schofield P., Mellor P.Buprenorphine to morphine transfer: an assessment in patients with advanced cancer pain. Pain1990; Suppl 5: S369.
23.
Fanciullacci M., Boccuni M., Pietrini V., Sicuteri F.Search for opiate receptors in the human pupil . Int J Clin Pharmacol Res1981; 1: 139-43.
Bianchi G., Ferretti P., Recchia M., Rocchetti M., Tavani A., Manara L.Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut. Gastroenterology1983; 85: 852-58.
26.
Yaksh TL, Rudy TAAnalgesia mediated by direct spinal action of narcotics. Science1976; 192: 1357-58.
Horwell DCKappa opioid analgesics. Drugs of the Future.1988; 13: 1061-71.
29.
Moulin DE, Ling Gsf, Pasternak GWUnidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain1988; 33: 233-39.
30.
Hoskin PJ, Hanks GW, Aherne GW, Chapman D., Littleton P., Filshie J.The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol1989; 27: 499-505.
31.
Gourlay GK, Cherry DA, Cousins MJA comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain1986; 25: 297-312.
32.
Sawe J., Dahlstrom B., Paalzow L., Rane A.Morphine kinetics in cancer patients. Clin Pharmacol Ther1981; 30: 629-35.
33.
Sawe J., Kager L., Svensson J-O., Rane A.Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation . Br J Clin Pharmacol1985; 19: 495-501.
34.
Sawe J., Svensson J-O., Rawe A.Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol1983; 16: 85-93.
35.
Hasselstrom J. , Eriksson LS, Persson A., Rane A., Svensson J., Sawe J.Morphine metabolism in patients with liver cirrhosis. Proceedings 3rd World Conference on Clinical Pharmacology and Therapeutics, 1986: 101.
36.
Mazoit JX, Sardouk P., Zetlaoui P., Scherrmann JMPharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anaesth Analg1987; 66: 293-98.
37.
Moore A., Sear J., Baldwin D. et al. Morphine kinetics during and after renal transplantation. Clin Pharmacol Ther1984; 35: 641-45.
38.
Aitkenhead AR, Vater M., Achola K., Cooper MS, Smith G.Pharmacokinetics of single dose IV morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth1984; 56: 813-19.
39.
Sawe J., Svensson JO, Odar-Cederlof I.Kinetics of morphine in patients with renal failure. Lancet1985; ii: 211.
40.
Woolner DF, Winter D., Frendin TJ et al. Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol1986; 22: 55-59.
41.
Walsh CT, Levine RRStudies of the enterohepatic circulation of morphine in the rat. J Pharmacol Exp Ther1975; 195: 303-10.
42.
Garrett ER, Jackson AJPharmacokinetics of morphine and its surrogates III: morphine and morphine-3-monoglucuronide pharmacokinetics in the dog as a function of dose. J Pharm Sci1979; 68: 753-71.
43.
Hanks GW, Wand PJEnterohepatic circulation of opioid drugs. Is it clinically relevant in the treatment of cancer patients?Clin Pharmacokinet1989; 17: 65-68.
44.
Leslie ST, Rhodes A., Black FMControlled release morphine sulphate tablets - a study in normal volunteers . Br J Clin Pharmacol1980; 9: 531-34.
45.
Poulain P., Hoskin PJ, Hanks GW, A-Omar O., Walker VA et al. Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesth1988; 61: 569-74.
46.
Hanks GW, Hoskin PJ, Aherne GW, Chapman D., Turner P., Poulain P.Enterohepatic circulation of morphine. Lancet1988; i: 469.
47.
Shimomura K. , Kannata O., Ueki S. et al. Analgesic effect of morphine glucuronides . Tohoku J Exp Med1971; 105: 45-52.
48.
Sullivan AF , McQuay HJ, Bailey D., Dickenson AHThe spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. Brain Res1989; 482: 219-24.
49.
Osborne R., Joel S., Trew D., Slevin M.Analgesic activity of morphine-6-glucoronide. Lancet1988; i: 828.
50.
Hanna M. et al. The analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide in patients with cancer pain: comparison with intrathecal morphine. Pain1989; Suppl 5: S199.
51.
Hanna M. et al. Morphine-6-glucuronide: assessment of respiratory effects in man. Journal of the Intractable Pain Society1989; 7: 53.
52.
Hanna M. et al. Morphine-6-glucuronide: pharmacokinetics and side effects following intravenous administration to man. Journal of the Intractable Pain Society1990; 7: 53.
53.
Thompson PI , Bingham S., Andrews Plr, Slevin MLComparative emetic potency of morphine and its active metabolite morphine-6-glucuronide in the ferret. Pain1990; Suppl 5: S180.
54.
Smith MT, Cramond T.Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Pain1990; Suppl 5: S186.
55.
Beecher HK, Keats AS, Mosteller F., Lasagna L.The effectiveness of oral analgesics (morphine, codeine, acetysalicylic acid) and the problem of placebo 'reactors' and 'non-reactors'. J Pharmacol Exp Ther1953; 109: 393-400.
56.
Hand CW, Blunnie WP, Claffey LP, McShane AJ, McQuay HJ, Moore RAPotential analgesic contribution from morphine-6-gluruconide in CSF. Lancet1987; ii: 1207-8.
57.
Hoskin PJ, Hanks GW, Heron CW, Aherne GW, Chapman DJM6G and its analgesic action in chronic use. The Clinical Journal of Pain1989; 5: 199-201.
58.
Poulain P., Moran-Ribon A., Hanks GW, Hoskin PJ, Aherne GW, Chapman DJCSF concentrations of morphine-6-glucuronide after oral administration of morphine. Pain1990; 41: 115-16.
59.
Houde RW et al. Clinical measurement of pain. In: de Stevens G ed, Analgetics. New York : Academic Press, 1965.
60.
Twycross RG, Lack SASymptom control in far advanced cancer: pain relief. London : Pitman. 1983: 168.
61.
World Health Forum. 1987; 8: 525-29.
62.
Twycross RGRelief of pain: strong narcotic analgesics. In: Saunders CM ed. The management of terminal malignant disease , second ed. London: Edward Arnold . 1985: 75-81.
63.
Plummer JL, Goulay GK, Cherry DA, Cousins MJEstimation of methadone clearance: application in the management of cancer pain. Pain1988; 33: 313-22.
64.
Grochow L., Sheidler V., Grossman S., Green L., Enterline J.Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomised, double-blind study. Pain1989; 38: 151-57.
65.
Inturissi CE , Max MB, Foley KM et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med1984; 310: 1213-17.
66.
Way EL, Young JM, Kemp KWMetabolism of heroin and its pharmacologic implications. Bull Narc1965; XVII (1): 25-33.
67.
Houde RWClinical analgesic studies of hydromorphone. In: Foley KM, Inturrisi CE eds, Advances in pain research and therapy, Vol 8. New York: Raven Press. 1986: 129-35.
68.
Steinberg SK , Kornijenko M.The role of hydromorphone in the treatment of cancer pain. Canadian Pharmaceutical Journal1988; March: 182-86.
69.
O'Flaherty D., Szekely S., Vickers MDTramadol versus pethidine analgesia in post-operative pain. Pain1990; Suppl 5: S179.
70.
Budd K.The dose response curve for tramadol hydrochloride in man. Pain1990; Suppl 5: S268.
71.
Tawfik MO, Elborolossy K., Nasr F.Tramadol hydrochloride in the relief of cancer pain. A double blind comparison against sustained release morphine. Pain1990 ; Suppl 5: S377.
72.
Lachmann B. , Voets M., Haumes RJ, Verkaaik A., Erdman W.Tramadol hydrochloride: absence of respiratory depression compared to morphine in postoperative pain relief. Pain1990; Suppl 5: S268.
73.
Regnard Cfb , Badger C.Opioids, sleep and the time of death. Palliative Medicine1989; 8: 1-2.
74.
Hanks GW, Twycross RG, Lloyd JWUnexpected complication of a successful nerve block. Anaesthesia1981; 36: 37-39.
75.
Arita H., Kogo N., Ichikawa K.Locations of medullary neurones with non-phasic discharges excited by stimulation of central and/or peripheral chemoreceptors and by activation of nociceptors in the cat. Brain Res1988; 442: 1-10.
76.
Woodcock AA , Gross ER, Gellert A., Shah S., Johnson M., Geddes DMEffect of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med1981; 305: 1611-16.
77.
Rogers PF, Barnes PJOpioid inhibition of neurally mediated mucous secretion in human bronchi. Lancet1989; i: 930-31.
78.
Wood HM, Cousins MJIatrogenic neurotoxicity in cancer patients. Pain1989; 39: 1-3.
79.
Bruera E., Macmillan K., Hanson J., MacDonald RN. The cognitive effect of the administration of narcotic analgesics in patients with cancer pain. Pain1989; 39: 13-16.
80.
Sjogren P., Banning A.Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain1989; 39: 5-11.
81.
Bruera E., Chadwick S., Brenneis C. et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep1987; 71: 67-70.
82.
Bruera E., Brenneis C., Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. Journal of Pain and Symptom Management1989; 4: 3-6.
83.
Potter JM, Reid DB, Shaw RJ, Hackett P., Hickman PEMyoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. Br Med J1989; 299: 150-53.
Bruera E., Miller MJNon-cardiogenic pulmonary oedema after narcotic treatment for cancer pain . Pain1989; 39: 297-300.
86.
Ali Nmk, Hoffman JSTolerance during long-term administration of intrathecal morphine. Conn Med1989; 53: 266-68.
87.
Twycross RGClinical experience with diamorphine in advanced malignant disease. IntJ Clin Pharmacol Ther Toxicol1974; 9: 184-98.
88.
Twycross RG, Wald SJLong-term use of diamorphine in advanced cancer. In: Bonica JJ, Albe-Fessard DG eds, Advances in pain research and therapy, Vol 1. New York: Raven Press. 1976: 653-61.
89.
Colpaert FC , Niemegeers Cje, Janssen Paj, Mareli ANThe effects of prior fentanyl administration and of pain on fentanyl analgesia: tolerance to and enhancement of analgesia . J Pharmacol Exp Ther1980; 213: 418-26.
90.
Joranson DE, Dahl JL, Angarola RTCancer pain: opioids and the law: balancing drug control and availability . Pain1990; Suppl 5: S371.
91.
Chapman CR, Hill HFProlonged morphine self administration and addiction liability. Cancer1989; 63: 1636-44.
92.
Creighton FJ, Ghodse AHNaloxone applied to conjunctiva as a test for physical opiate dependence. Lancet1989i: 748-50.
93.
Turnberg LAAntisecretory activity of opiates in vitro and in vivo in man. Scand J Gastronenterol [Suppl]1983; 84: 79.
94.
White ID, Hoskin PJ, Hanks GW, Bliss JMMorphine and dryness of the mouth. Br Med J1989; 298: 1222-23.
Lange DG, Rorig SC, Fujimoto JM, Wang Rih.Absence of cross tolerance to heroin in morphine-tolerant mice. Science1980; 208: 72-74.
97.
Manara L., Bianchetti A.The central and peripheral influence of opioids on gastrointestinal propulsion . Ann Rev Pharmacol Toxicol1985; 75: 249-73.
98.
Peracchia F. , Biachi G., Fiocchi R., Petrillo P., Tavani A., Manara L.Central and peripheral inhibition of gastrointestinal transit in rats: narcotics differ substantially by acting at either or both levels. J Pharm Pharmacol1984; 36: 699-701.
99.
Reboa G., Arnulfo G., Frascio M., Di-Soimma C., Pitta G., Berti-Riboli E.Colon motility and colorectal reflexes in chronic idiopathic constipation. Effects of a novel enterokinetic agent cisapride. Eur J Clin Pharmacol1984; 26: 745-48.
100.
Binnie NR, Creasey GH, Edmond P., Smith ANThe action of cisapride in the chronic constipation of paraplegia. Paraplegia1988; 26: 151-58.
101.
Bruera E., Brenneis C., Michaud M., MacDonald N.Continuous SC infusion of metoclopramide for treatment of narcotic bowel syndrome . Cancer Treat Rep1987; 71: 1121-22.
102.
Hanks GWAnti-emetics for terminal cancer patients. Lancet1982; i: 1410.
103.
Cunningham D.Prevention of emesis in patients, receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist . Lancet1987; i: 1461-63.
104.
Hoskin PJ, Hanks GWThe management of symptoms in advanced cancer: experience in a hospital-based continuing care unit. J R Soc Med1988; 81: 341-44.
105.
Hanks GW, Twycross RG, Bliss JMControlled release morphine tablets: a double blind trial in patients with advanced cancer. Anaesthesia1987; 42: 840-44.
106.
Hoskin PJ, Poulain P., Hanks GWControlled-release morphine in cancer pain. Is a loading dose required when the formulation is changed?Anaesthesia1989 ; 44: 897-901.
107.
McQuay HJ, Moore RA, Bullingham Res.Sublingual morphine, heroin, methadone and buprenorphine: kinetics and effect . In: Foley KM, Inturrisi CE eds, Advances in pain research and therapy , Vol 8. New York: Raven Press. 1986: 407-11.
108.
Ellison WM , Lewis GOPlasma concentrations following single doses of morphine sulphate in oral solution and rectal suppository. Clin Pharm1984; 3: 614-17.
109.
Twycross PG, Lack SASymptom control in far advanced cancer: pain relief. London : Pitman. 1983: 211.
110.
Maloney CM , Kesner RK, Klein G., Bockenstette J.The rectal administration of MS Contin: clinical implications of use in end stage cancer. American Journal of Hospice Care1989; July/Aug: 34-35.
111.
Kaiko RF, Healy N., Pav J., Thomas GB, Goldenheim PDThe comparative bioavailability of MS Contin tablets (controlled release morphine) following rectal and oral administration. In: Twycross RG ed, The Edinburgh Symposium on Pain Control and Medical Education. London: Royal Society of Medicine. Symposium Series, Number 149: 235-41.
112.
Hanning CD , Smith G., McNeill M., Graham NBRectal administration of morphine from a sustained release hydrogel suppository. Br J Anaesth1983; S5: 236P-237P.
113.
Westerling D., Andersson KERectal administration of morphine hydrogel: absorption and bioavailability in women. Acta Anaesthesiol Scand1984; 28: 540-43.
114.
Breimer D.Rate-controlled rectal drug delivery - an alternative to IV injection. The Pharmaceutical Journal1989; 242: 257.
115.
Waldmann CS , Eason JR, Rambohul EM, Hanson GCSerum morphine levels: a comparison between continuous subcutaneous infusion and continuous intravenous infusions in post-operative patients. Anaesthesia1984; 39: 768-71.
116.
Drexel H., Dzien A., Spiegel RW et al. Treatment of severe cancer pain by low-dose subcutaneous morphine . Pain1989; 36: 169-76.
117.
McDonald P., Gorman DJ, Little B., Stuart-Harris R.Subcutaneous (SC) morphine by four-hourly bolus for pain control in advanced cancer. Proceedings of the Clinical Oncology Society of Australia. December, 1988.
118.
Miser AW, Narang PK, Dothage JA, Young RC, Sindelar W., Miser JSTransdermal fentanyl for pain control in patients with cancer. Pain1989; 37: 15-21.
119.
Yusef S., Simon R., Ellenberg S.Proceedings of the workshop on methodologic issues in overviews of randomised clinical trials. Stat Med 1987 ; 6: 217-409.
120.
Morgan M.The rational use of intrathecal and extradural opioids. Br J Anaesth1989; 63: 165-88.
121.
Mather LE, Cousins MJPharmacology of opioids. Part 2: clinical aspects. Med J Aust1986; 144: 475-81.
122.
Vainio A., Tigerstcott I.Opioid treatment for radiating cancer pain: oral administration vs epidural techniques. Acta Anaesthesiol Scand1988; 32: 179-85.
123.
Driessen JJ, de Mulder Phm, Claessen Jjl, van Diejen D., Wobbes Th.Epidural administration of morphine for control of cancer pain: long-term efficacy and complications. The Clinical Journal of Pain1989; 5: 217-22.
124.
Hardy Paj, Wells Jcd.Prediction of intrathecal opioid response: a preliminary study using fentanyl . The Pain Clinic1988; 2: 45-47.
125.
Hardy Paj, Wells Jcd.Patient-controlled intrathecal morphine for cancer pain. A method used to assess morphine requirements and bolus doses. TheClinical Journal of Pain1990; 6: 57-59.
126.
Twycross RG, Lack SASymptom control in far advanced cancer: pain relief. London : Pitman. 1984: 112.
Arner S., Arner B.Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand1985; 29: 32-36.
129.
Chauvin M. , Samii K., Schermann JM, Sandouk P., Bourdon R., Viars P.Plasma concentration of morphine after IM, extradural and intrathecal administration. Br J Anaesth1981; 53: 911-13.
130.
Liew E., Hui YLA preliminary study of longterm epidural morphine for cancer pain via a subcutaneously implanted reservoir. Ma Tsui Hsueh Tsa Chi.1989; 27: 5-12.
131.
Gonzalez-Naverro A., Molinero-Aparicio T., Manzo L.Cancer pain and intrathecal morphine. Palliative Medicine1989; 3: 287-92.
132.
Ventafridda V. , De Conno F., Tamburini M., Pappalettera M.Clinical evaluation of chronic infusion of intrathecal morphine in cancer pain. In: Foley KM, Inturrisi CE eds, Advances in pain research and therapy. Vol 8. New York: Raven Press. 1986: 391-97.
133.
Madrid JL, Fatela LV, Alcorta J., Guillen F., Lobato RDIntermittent intrathecal morphine by means of an implantable reservoir: a survey of 10 cases. Journal of Pain and Symptom Management1988; 3: 67-71.
134.
Chambers WA , Sinclair CJ, Scott DBExtradural morphine for pain after surgery . Br J Anaesth1981; 53: 921-24.
135.
Cullen ML, Staren ED, El-Ganzouri A., Logas WG, Ivankovitch AD, Economou SGContinuous epidural infusion for analgesia after major abdominal operations: a randomised, prospective, double-blind study. Surgery1985; 98: 718-26.
136.
Obbens Eamt , Stratton Hill C., Leavens ME, Ruthenbeck SS, Otis F.Intraventricular morphine administration for control of chronic cancer pain. Pain1981; 28: 61-68.
137.
Nurchi G.Use of intraventricular and intrathecal morphine in intractable pain associated with cancer. Neurosurgery1984; 15: 801-803.
138.
Roquefeuil B., Benezech J., Blanchet P., Batier C., Frerebeau P., Gros C.Intraventricular administration of morphine in patients with neoplastic intractable pain. Surg Neurol1984; 21: 155-58.
139.
Poletti CE , Cohen AM, Todd DP, Ojemann RG, Sweet WHZervas WTCancer pain relieved by longterm epidural morphine with permanent indwelling systems for self-administration. J Neurosurg1981; 55: 581-84.
140.
Kiss IE, Simini B., May JWEffect of epidural morphine on various kinds of cancer pain. Palliative Medicine1989; 3: 217-21.
141.
Crawford ME , Anderson H., Augustenborg G. et al. Pain treatment on outpatient basis utilizing extradural opiates. A Danish multicentre study comprising 105 patients . Pain1983; 16: 41-47.
142.
Downing JE , Busch EH, Stedman PMEpidural morphine delivered by a percutaneous epidural catheter for outpatient treatment of cancer pain. Anaesth Analg1988; 67: 1159-61.
143.
Malone BT, Beye R., Walker J.Management of pain in the terminally ill by administration of epidural narcotics . Cancer1985; 55: 438-40.
144.
Carl P., Crawford ME, Ravlo O., Bach V.Long-term treatment with epidural opioids. Anaesthesia1986; 41: 32-38.
145.
Findler G. , Olshwang D., Hadani M.Continuous epidural morphine treatment for intractable pain in terminal cancer patients. Pain1982; 14: 311-15.
146.
Chabal C., Buckley FP, Jacobson L., Butler S., Murphy T.Long-term epidural morphine in the treatment of cancer pain. The Pain Clinic1989; 3: 19-23.
147.
Coombs DW, Maurer LH, Saunders RL, Gaylor M.Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control. J Clin Oncol1984; 2: 1414-20.
